Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hervé Watier

Showing results (1-10 of 112) with videos related to

Pageof 12
Sort By:
Expert Opinion on Biological Therapy|September 29, 2005
Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteinsHervé Watier
Oncotarget|September 15, 2018
Rituximab mechanisms of action in B-CLL: a new piece of the puzzleHervé Watier
Medecine Sciences : M/S|December 29, 2009
[From the ancient serotherapy to naked antibodies: a century of successful targeted therapies]Hervé Watier
Medecine Sciences : M/S|June 19, 2014
[Biotherapies, immunotherapies, targeted therapies, biopharmaceuticals… which word should be used?]Hervé Watier
La Revue Du Praticien|December 12, 2012
[Serotherapy, among therapeutic innovations and scientific progress in the late 19th and 20th centuries]Arnaud Daguet, Hervé Watier
Blood|June 7, 2017
Obinutuzumab: what is there to learn from clinical trials?Guillaume Cartron, Hervé Watier
Medecine Sciences : M/S|December 29, 2009
[Therapeutic monoclonal antibodies in the French community: let's get organized]Delphine Watiez, Hervé Watier
Medecine Sciences : M/S|January 7, 2020
[Which immunoglobulin heavy chains for which immunostimulatory antibodies?]Christophe Dumet, Hervé Watier
Mabs|August 23, 2011
2nd Charles Richet et Jules Héricourt workshop: therapeutic antibodies and anaphylaxis; May 31-June 1, 2011, Tours, FranceArnaud Daguet, Hervé Watier
Blood|January 29, 2011
Bacteria and HIT: a close connection?Yves Gruel, Hervé Watier
Pageof 12

Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
Expert Opinion on Biological Therapy|September 29, 2005
Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteinsHervé Watier
Oncotarget|September 15, 2018
Rituximab mechanisms of action in B-CLL: a new piece of the puzzleHervé Watier
Medecine Sciences : M/S|December 29, 2009
[From the ancient serotherapy to naked antibodies: a century of successful targeted therapies]Hervé Watier
Medecine Sciences : M/S|June 19, 2014
[Biotherapies, immunotherapies, targeted therapies, biopharmaceuticals… which word should be used?]Hervé Watier
La Revue Du Praticien|December 12, 2012
[Serotherapy, among therapeutic innovations and scientific progress in the late 19th and 20th centuries]Arnaud Daguet, Hervé Watier
Blood|June 7, 2017
Obinutuzumab: what is there to learn from clinical trials?Guillaume Cartron, Hervé Watier
Medecine Sciences : M/S|December 29, 2009
[Therapeutic monoclonal antibodies in the French community: let's get organized]Delphine Watiez, Hervé Watier
Medecine Sciences : M/S|January 7, 2020
[Which immunoglobulin heavy chains for which immunostimulatory antibodies?]Christophe Dumet, Hervé Watier
Mabs|August 23, 2011
2nd Charles Richet et Jules Héricourt workshop: therapeutic antibodies and anaphylaxis; May 31-June 1, 2011, Tours, FranceArnaud Daguet, Hervé Watier
Blood|January 29, 2011
Bacteria and HIT: a close connection?Yves Gruel, Hervé Watier
Pageof 12